专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2021026182A1 PROCESS-SCALE SYNTHESIS OF A PLASMA KALLIKREIN INHIBITOR 审中-公开
公开(公告)号：WO2021026182A1
公开(公告)日：2021-02-11
申请号：PCT/US2020/044921
申请日：2020-08-05
申请人： BIOCRYST PHARMACEUTICALS, INC.
发明人： EL-KATTAN, Yahya , BABU, Yarlagadda S.
IPC分类号： C07D231/14 , C07C237/40 , C07C231/02
摘要： Disclosed are methods of preparing Compound (I), and salts thereof. The methods of preparing Compound (I) are suitable for use on process scale.

2. 发明申请

WO2011031554A2 HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS 审中-公开
标题翻译：作为JANUS激酶抑制剂的杂环化合物
公开(公告)号：WO2011031554A2
公开(公告)日：2011-03-17
申请号：PCT/US2010/046999
申请日：2010-08-27
申请人： BIOCRYST PHARMACEUTICALS, INC. , BABU, Yarlagadda S. , KOTIAN, Pravin L. , KUMAR, V. Satish , WU, Minwan , LIN, Tsu-Hsing
发明人： BABU, Yarlagadda S. , KOTIAN, Pravin L. , KUMAR, V. Satish , WU, Minwan , LIN, Tsu-Hsing
IPC分类号： C07D487/04
CPC分类号： C07D487/04
摘要： The invention provides compounds of formula (I) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using compounds of formula (I).
摘要翻译：本发明提供如本文所述的式（I）的化合物或其盐。本发明还提供了包含式（I）化合物的药物组合物，制备式（I）化合物的方法，可用于制备式I化合物的中间体和使用化合物抑制免疫应答或治疗癌症或血液恶性肿瘤的治疗方法的式（I）。

3. 发明申请

WO2012106448A1 HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS 审中-公开
标题翻译：杂环化合物作为JANUS KINASE INHIBITORS
公开(公告)号：WO2012106448A1
公开(公告)日：2012-08-09
申请号：PCT/US2012/023510
申请日：2012-02-01
申请人： BIOCRYST PHARMACEUTICALS, INC. , BABU, Yarlagadda S. , KOTIAN, Pravin L. , RAMAN, Krishnan
发明人： BABU, Yarlagadda S. , KOTIAN, Pravin L. , RAMAN, Krishnan
IPC分类号： A61K31/5025
CPC分类号： C07D487/16 , C07D487/22
摘要： The invention provides compounds of formula (I) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula (I), and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using compounds of formula (I).
摘要翻译：本发明提供了本文所述的式（I）化合物或其盐。本发明还提供了包含式（I）化合物，制备式（I）化合物的方法，用于制备式（I）化合物的中间体以及抑制免疫应答或治疗癌症或血液学的治疗方法的药物组合物使用式（I）化合物的恶性肿瘤。

4. 发明申请

WO2011014817A1 PYRROLO [1, 2-B] PYRIDAZINE DERIVATIVES AS JANUS KINASE INHIBITORS 审中-公开
标题翻译：吡咯烷[1,2-B]吡嗪类衍生物作为JANUS KINASE INHIBITORS
公开(公告)号：WO2011014817A1
公开(公告)日：2011-02-03
申请号：PCT/US2010/043987
申请日：2010-07-30
申请人： BIOCRYST PHARMACEUTICALS, INC. , BABU, Yarlagadda S. , KOTIAN, Pravin L. , KUMAR, V. Satish , WU, Minwan , LIN, Tsu-Hsing
发明人： BABU, Yarlagadda S. , KOTIAN, Pravin L. , KUMAR, V. Satish , WU, Minwan , LIN, Tsu-Hsing
IPC分类号： C07D487/04 , A61K31/5025 , A61P35/00
CPC分类号： C07D487/04
摘要： The invention provides compounds of formula l: ( I ) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using compounds of formula I.
摘要翻译：本发明提供了本文所述的式I化合物或其盐。本发明还提供包含式I化合物的药物组合物，制备式I化合物的方法，可用于制备式I化合物的中间体和使用式I化合物抑制免疫应答或治疗癌症或血液恶性肿瘤的治疗方法。

5. 发明申请

WO2010036407A2 ANTIVIRAL NUCLEOSIDE ANALOGS 审中-公开
标题翻译：抗病毒核苷类似物
公开(公告)号：WO2010036407A2
公开(公告)日：2010-04-01
申请号：PCT/US2009/044214
申请日：2009-05-15
申请人： BIOCRYST PHARMACEUTICALS, INC. , BABU, Yarlagadda S. , CHAND, Pooran , KUMAR, V. Satish , HU, Xingding
发明人： BABU, Yarlagadda S. , CHAND, Pooran , KUMAR, V. Satish , HU, Xingding
IPC分类号： A61K31/53 , A61K31/519 , C07H7/06 , A61P31/12 , A61P35/00
CPC分类号： A61K31/519 , A61K31/53 , Y02A50/393 , Y02A50/465
摘要： The invention provides compounds as described herein, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates that are useful for preparing the compounds. The compounds are useful as anti-viral agents and/or as anti-cancer agents.
摘要翻译：本发明提供了如本文所述的化合物，以及包含所述化合物的药物组合物，以及可用于制备所述化合物的合成方法和中间体。这些化合物可用作抗病毒剂和/或作为抗癌剂。

6. 发明申请

WO2022140250A1 DOSING REGIMENS FOR ORAL ALK2 KINASE INHIBITORS 审中-公开
公开(公告)号：WO2022140250A1
公开(公告)日：2022-06-30
申请号：PCT/US2021/064333
申请日：2021-12-20
申请人： BIOCRYST PHARMACEUTICALS, INC.
发明人： BABU, Yarlagadda S. , SHERIDAN, William P.
IPC分类号： A61K31/4164 , A61K31/519 , C07D233/54 , C07D487/04 , A61P35/00
摘要： Disclosed are dosage forms of compounds and pharmaceutically acceptable salts thereof, which are inhibitors of ALK2 kinase, including mutant forms of ALK2. Also disclosed are methods of using the oral dosage forms in the treatment or prevention of a disease or condition whose treatment would benefit from ALK2 kinase inhibition (e.g., Fibrodysplasia Ossificans Progressiva and cancer).

7. 发明申请

WO2021207386A1 METHODS, COMPOSITIONS, AND DOSING REGIMENS FOR TREATMENT OF SARS-COV-2 INFECTIONS 审中-公开
公开(公告)号：WO2021207386A1
公开(公告)日：2021-10-14
申请号：PCT/US2021/026222
申请日：2021-04-07
申请人： BIOCRYST PHARMACEUTICALS, INC.
发明人： BABU, Yarlagadda S. , MATHIS, Amanda , SHERIDAN, William P.
IPC分类号： A61K31/519 , A61K31/7064 , A61P31/12
摘要： Provided are compounds of the formula I and pharmaceutically acceptable salts, solvates, and hydrates thereof, for use in treating or suppressing a SARS-CoV-2 infection in a subject. A novel dosing regimen for administration of the disclosed compounds is also provided comprising administering at least one loading dose and at least one maintenance dose of the disclosed compound. The compounds of the disclosure are characterized, in part, by favorable pharmacokinetics for the active pharmaceutical ingredient, particularly in conjunction with the dosing regimen described.

8. 发明申请

WO2017155886A1 METHODS AND COMPOSITIONS FOR TREATMENT OF ZIKA VIRUS INFECTION 审中-公开
标题翻译：治疗ZIKA病毒感染的方法和组合物
公开(公告)号：WO2017155886A1
公开(公告)日：2017-09-14
申请号：PCT/US2017/020961
申请日：2017-03-06
申请人： BIOCRYST PHARMACEUTICALS, INC.
发明人： BABU, Yarlagadda S. , KOTIAN, Pravin L. , BANTIA, Shanta
IPC分类号： C07D487/04 , C07D471/04
摘要： The present disclosure is directed to methods and compositions that are useful in combating the spread of Zika virus infections, such as, but not limited to, methods and compositions for treating, preventing or suppressing a Zika virus infection in a subject. The methods comprise administering to the subject an effective amount of a compound of the disclosure, or a composition (such as a pharmaceutical composition) comprising a compound of the disclosure.
摘要翻译：本公开涉及用于对抗寨卡病毒感染的传播的方法和组合物，所述传播例如但不限于用于治疗，预防或抑制寨卡病毒感染的方法和组合物在一个主题。所述方法包括向受试者施用有效量的本公开化合物或包含本公开化合物的组合物（例如药物组合物）。

9. 发明申请

WO2016029214A1 COMPOSITIONS AND USES OF AMIDINE DERIVATIVES 审中-公开
标题翻译：氨基衍生物的组成和用途
公开(公告)号：WO2016029214A1
公开(公告)日：2016-02-25
申请号：PCT/US2015/046578
申请日：2015-08-24
申请人： BIOCRYST PHARMACEUTICALS, INC.
发明人： BABU, Yarlagadda S. , KAMATH, Vivekanand P. , GOWAN, Walter
IPC分类号： A61K9/08 , A61P7/10 , C07D213/81 , A61K31/44
CPC分类号： A61K31/4418 , A61K9/0053 , A61K9/0095 , A61K9/4858 , A61K9/4866
摘要： Use of a compound of formula (I): wherein A, X, Y, R 1 and R 2 as defined herein, in treating hereditary angioedema is disclosed. A composition containing the compounds, a polar organic solvent or a mixture thereof; and optionally a co-solvent, is also disclosed.
摘要翻译：公开了式（I）化合物：其中本文定义的A，X，Y，R 1和R 2在治疗遗传性血管性水肿中的用途。含有化合物，极性有机溶剂或其混合物的组合物; 和任选的共溶剂。

10. 发明申请

WO2017035263A1 COMPOSITIONS COMPRISING A PLASMA KALLIKREIN INHIBITOR 审中-公开
标题翻译：包含等离子卡耳列汀抑制剂的组合物
公开(公告)号：WO2017035263A1
公开(公告)日：2017-03-02
申请号：PCT/US2016/048456
申请日：2016-08-24
申请人： BIOCRYST PHARMACEUTICALS, INC.
发明人： BABU, Yarlagadda S. , BLOOM, Corey J. , BONE, Scott Joseph , KAUSHAL, Aditya Mohan
IPC分类号： A61K9/08 , A61K31/44 , C07D213/81
CPC分类号： A61K31/44 , A61K9/2027 , A61K9/2054 , A61K9/2077
摘要： The present disclosure provides for compositions comprising 3-[2-(4-carbamimidoyl- phenylcarbamoyl)-5-methoxy-4-vinyl-phenyl]-6-(cyclopropylmethyl-carbamoyl)-pyridine-2- carboxylic acid, or a pharmaceutically acceptable form thereof, and a matrix, particularly compositions comprising a solid dispersion or combination of 3-[2-(4-carbamimidoyl- phenylcarbamoyl)-5-methoxy-4-vinyl-phenyl]-6-(cyclopropylmethyl-carbamoyl)-pyridine-2- carboxylic acid, or a pharmaceutically acceptable form thereof, and a concentration enhancing polymer. The compositions provide for higher exposure of 3-[2-(4-carbamimidoyl- phenylcarbamoyl)-5-methoxy-4-vinyl-phenyl]-6-(cyclopropylmethyl-carbamoyl)-pyridine-2- carboxylic acid in the blood for a given dose while at the same time provide for a higher concentration of 3-[2-(4-carbamimidoyl-phenylcarbamoyl)-5-methoxy-4-vinyl-phenyl]-6- (cyclopropylmethyl-carbamoyl)-pyridine-2-carboxylic acid in the blood over time. Dosage forms, dosing protocols and methods of treatment are also provided.
摘要翻译：本公开内容提供了包含3- [2-（4-甲脒基 - 苯基氨基甲酰基）-5-甲氧基-4-乙烯基 - 苯基] -6-（环丙基甲基 - 氨基甲酰基） - 吡啶-2-甲酸或其药学上可接受的组合物特别是包含固体分散体或3- [2-（4-甲脒基 - 苯基氨基甲酰基）-5-甲氧基-4-乙烯基 - 苯基] -6-（环丙基甲基 - 氨基甲酰基） - 吡啶-2-基的组合的组合物， 2-羧酸或其药学上可接受的形式和浓度增强聚合物。该组合物提供3- [2-（4-甲脒基 - 苯基氨基甲酰基）-5-甲氧基-4-乙烯基 - 苯基] -6-（环丙基甲基 - 氨基甲酰基） - 吡啶-2-甲酸在血液中的较高的暴露量给定剂量，同时提供更高浓度的3- [2-（4-氨甲酰氨基 - 苯基氨基甲酰基）-5-甲氧基-4-乙烯基 - 苯基] -6-（环丙基甲基 - 氨基甲酰基） - 吡啶-2-甲酸随着时间的推移，血液中的酸变酸。还提供了剂量形式，给药方案和治疗方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式